Healthcare Industry News: osteoporosis
News Release - September 29, 2009
Hologic Receives CE Marking for the ThinPrep(R) Integrated ImagerBEDFORD, Mass., Sept. 29 (Healthcare Sales & Marketing Network) -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager. The ThinPrep integrated imager was introduced and on display at the 35th European Congress of Cytology this week in Lisbon, Portugal.
The integrated imager represents the latest innovation in cervical cancer screening by combining proven ThinPrep imaging technology and slide review into a single, convenient stand-alone device. This exciting new product offering allows laboratories of all sizes to benefit from clinical advantages of ThinPrep imaging for cervical screening.
"This represents a tremendous opportunity for Hologic and our current and future laboratory partners throughout Europe," said Howard Doran, senior vice president, diagnostics products for Hologic. "The ThinPrep integrated imager is designed to provide the small and medium volume laboratory access to the most effective and efficient cytology screening technology available, while allowing them the flexibility to address their specific productivity and throughput needs." The majority of laboratories in Europe would fall into the small or medium category.
The integrated imager analyzes a ThinPrep Pap test slide in approximately 90 seconds, during which time each cell and cell cluster is scanned. Using optical density analysis, the integrated imager identifies diagnostically-relevant cells or cell groups and then stores coordinates of the 22 fields of interest. These 22 fields of interest are presented to the cytotechnologist for interpretation. If no abnormalities are identified by the cytotechnologist, the slide can be signed out as negative or proceed through the laboratory quality control system. A complete slide review is required if the user detects any suspicious cells within the 22 fields of view. This dual review process combines human interpretative expertise with the power of computer imaging.
Hologic's experience working with ThinPrep Pap test users contributed significantly to the integrated imager development. Every feature is designed to enable the cytotechnologist to perform slide review effectively and efficiently. The integrated imager can also be used as a conventional microscope saving valuable lab space.
CE marking approval allows Hologic to market the ThinPrep integrated imager in the 27 countries of the European Union (EU) and three of the four member states of the European Free Trade Association (EFTA). CE marking is recognized in many countries outside the European Economic Area giving Hologic the ability to supply systems to a number of markets internationally. The ThinPrep integrated imager is currently not approved by the U.S. Food and Drug Administration.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Forward-Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the ThinPrep Pap test, ThinPrep imaging system and the ThinPrep integrated imager. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner by a particular laboratory as the actual effect of the use of the ThinPrep Pap test, ThinPrep imaging system and the ThinPrep integrated imager can only be determined on a case-by-case basis depending on the particular laboratory, screening personnel and patient sample in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Hologic and ThinPrep are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.